- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04200937
IT Matters: The Erectile Restoration Registry (It MATTERS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
Los Angeles, California, United States, 99048
- Tower Urology-Research Facility
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Hospital
-
Tampa, Florida, United States, 33606
- USF Health South Tampa Center for Advanced Healthcare
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Springfield, Illinois, United States, 62702
- SIU School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Medical Center
-
-
Louisiana
-
Bossier City, Louisiana, United States, 71111
- Willis-Knighton Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
- Duke University Medical Center
-
Salisbury, North Carolina, United States, 28144
- W.G. Hefner VA Medical Center
-
Winston-Salem, North Carolina, United States, 27103
- Wake Forest University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males who are >/= 18 years of age.
- Males with chronic, organic, erectile dysfunction (impotence) who are determined to be suitable candidates for implantation surgery by their physician.
- Willing and able to undergo surgical implantation of a study BSC penile prothesis device.
- Willing and able to complete the informed consent process.
- Willing and able to comply with the follow-up requirement.
Exclusion Criteria:
1. Men who are deemed by their physician as not suitable for a penile prothesis will be excluded per the contraindications in each study device's Instructions for Use (IFU).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
BSC Penile Prothesis Recipients
Men for whom BSC Penile Prothesis is recommended.
|
The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to six months in the Erectile Function domain of the International Index of Erectile Function (IIEF-EF) questionnaire
Time Frame: Baseline to 6 months
|
The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30). |
Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depressive symptoms and overall sexual function at Post-Surgery, 6 months, 12 months and annually thereafter post device implantation compared to baseline, as measured by the PHQ-9 Depression Questionnaire and the IIEF: Total Score.
Time Frame: Post-Surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
|
The Patient Health Questionnaire (PHQ) is a diagnostic tool for mental health disorders used by health care professionals.
The PHQ contains: mood anxiety, alcohol, eating, and somatoform modules.
The PHQ-9, is a validated tool specific to depression, scoring each of the 9 DSM-IV criteria.
Scored from 0-27, the PHQ-9 is separated into five different diagnoses: minimal depression (0-4), mild depression (5-9), moderate depression (10-14), moderately severe depression (15-19), and severe depression (20-27).
|
Post-Surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
|
Change in quality of life at 6 months, 12 months, and 24 months post device implantation compared to baseline as measured by the WPAI:GH Questionnaire.
Time Frame: 6 months, 12 months and 24 months
|
The WPAI:GH (Work Productivity and Activity Impairment Questionnaire: General Health) is a validated tool that asks a series of questions about the effect of subject health problems, both physical and emotional, on their ability to work and perform regular activities.
The WPAI:GH outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes, as following 6 questions: 1 = currently employed, 2 = hours missed due to health problems, 3 = hours missed other reasons, 4 = hours actually worked, 5 = degree health affected productivity while working, 6 = degree health affected regular activities.
Scores are then multiplied by 100 to be expressed in percentages.
|
6 months, 12 months and 24 months
|
Change in erectile function at post-surgery, 12 months and annually post device implantation compared to baseline, as measured by the International Index of Erectile Function Domain (IIEF).
Time Frame: Post-Surgery, 12 months and annually thereafter through study completion, an average of 10 years
|
The International Index of Erectile Function (IIEF) is a validated, widely used, multidimensional self-report instrument for the evaluation of erectile function. It consists of 15 items that assess sexual function in five domains: erectile function (Q1, 2, 3, 4, 5,15), orgasmic function (Q9,10), sexual desire (Q11,12), intercourse satisfaction (Q 6,7,8) and overall satisfaction (Q 13,14). A score of 0-5 is awarded to each of the 15 questions. The IIEF-15 total score is the sum of the ordinal responses to the 5 domains. The erectile function (EF) domain is the most sensitive domain of the IIEF. IIEF-EF score ranges from 1 to 30 and is derived by scoring 0 (poorest function) to 5 (best function) on each of six questions function (Q1, 2, 3, 4, 5, 15). There are five categories of erectile function based on EF domain score: severe (1-10), moderate (11-16), mild to moderate (17-21), mild (22-25) and no ED (26-30). |
Post-Surgery, 12 months and annually thereafter through study completion, an average of 10 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device satisfaction at post-surgery, 6 months, 12 months and annually thereafter measured by the Likert scale.
Time Frame: Post-surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
|
The Likert scale has the options of Very Satisfied, Dissatisfied, Neither Satisfied nor Dissatisfied, Satisfied and Very Satisfied.
Responses will be evaluated categorically.
|
Post-surgery, 6 months, 12 months and annually thereafter through study completion, an average of 10 years
|
Assess for outcomes and adverse events on AMS Tools at Post Procedure.
Time Frame: Collected only at Post-Procedure
|
AMS tools will be assess by a physician survey as part of the post-procedure case report form.
|
Collected only at Post-Procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohit Khera, MD, Baylor College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- U0670
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Tactra Malleable
-
Lawson Health Research InstituteUnity Health Toronto; London Health Sciences CentreCompleted
-
Damanhour Teaching HospitalCompletedOrotracheal IntubationEgypt
-
Joint Implant Surgeons, Inc.Medtronic; Mount Carmel Health SystemCompletedArthritis, Rheumatoid | Osteonecrosis | Hip Dislocation, Congenital | Osteoarthritis, Hip | Joint Deformities, AcquiredUnited States